Wealth Enhancement Advisory Services LLC boosted its holdings in Amdocs Limited (NASDAQ:DOX – Free Report) by 193.7% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 141,793 shares of the technology company’s stock after purchasing an additional 93,511 shares during the quarter. Wealth Enhancement Advisory Services LLC owned about 0.13% of Amdocs worth $11,687,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in DOX. Dakota Wealth Management purchased a new stake in Amdocs during the second quarter valued at approximately $458,000. JPMorgan Chase & Co. raised its holdings in Amdocs by 13.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 266,124 shares of the technology company’s stock worth $24,281,000 after purchasing an additional 31,827 shares during the period. Farther Finance Advisors LLC increased its position in Amdocs by 64.5% in the second quarter. Farther Finance Advisors LLC now owns 1,625 shares of the technology company’s stock worth $148,000 after buying an additional 637 shares in the last quarter. Foster & Motley Inc. raised its stake in shares of Amdocs by 21.0% in the second quarter. Foster & Motley Inc. now owns 45,764 shares of the technology company’s stock worth $4,176,000 after buying an additional 7,934 shares during the period. Finally, Value Holdings Management CO. LLC lifted its position in shares of Amdocs by 56.5% during the 3rd quarter. Value Holdings Management CO. LLC now owns 77,575 shares of the technology company’s stock valued at $6,365,000 after buying an additional 28,000 shares in the last quarter. Hedge funds and other institutional investors own 92.02% of the company’s stock.
Amdocs Stock Performance
Shares of NASDAQ:DOX opened at $82.66 on Friday. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.23. Amdocs Limited has a 12 month low of $74.32 and a 12 month high of $95.41. The company has a market capitalization of $8.92 billion, a price-to-earnings ratio of 16.37, a PEG ratio of 1.41 and a beta of 0.40. The firm’s 50-day moving average is $79.65 and its 200 day moving average is $83.16.
Amdocs Announces Dividend
Analyst Ratings Changes
DOX has been the subject of several analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Amdocs in a report on Thursday, October 30th. Wall Street Zen lowered Amdocs from a “buy” rating to a “hold” rating in a research note on Saturday, January 3rd. Stifel Nicolaus decreased their price target on Amdocs from $100.00 to $97.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th. Wolfe Research reaffirmed a “peer perform” rating on shares of Amdocs in a research note on Thursday, November 13th. Finally, Bank of America decreased their target price on Amdocs from $100.00 to $97.00 and set a “buy” rating on the stock in a research note on Wednesday, November 12th. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $97.00.
Check Out Our Latest Stock Analysis on Amdocs
Amdocs Profile
Amdocs (NASDAQ: DOX) is a global software and services provider specializing in solutions for communications, media and entertainment companies. The company designs, develops and integrates revenue management, customer experience and digital services platforms that enable service providers to launch and monetize new offerings, streamline operations and enhance subscriber engagement. Amdocs’ product suite encompasses billing and order management, customer relationship management, digital commerce and network function virtualization, supported by professional services for implementation, integration and managed operations.
Founded in 1982 and structured as a separate public company in 1998, Amdocs has its corporate headquarters in Chesterfield, Missouri, and maintains major development centers in Ra’anana, Israel.
Featured Articles
- Five stocks we like better than Amdocs
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- The $100 Trillion AI Story No One Is Telling You
- Buy This Stock at 9:30 AM on MONDAY!
- A U.S. “birthright” claim worth trillions – activated quietly
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.
